ATLANTA, GA, USA I5, 2024 I UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with ...

The "Psoriatic Arthritis - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A notable advancement has been made within the Psoriatic Arthritis (PsA) therapeutic area, ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...

Biopharmaceutical company UCB has received US Food and Drug Administration (FDA) approval for BIMZELX (bimekizumab-bkzx) to ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

UCB announced the FDA has approved BIMZELX for the treatment of adults with active psoriatic arthritis, adults with active ...

The FDA cleared Bimzelx to treat adults with active psoriatic arthritis (PsA), active non-radiographic axial ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

The FDA has approved Bimzelx (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial ...

Many Americans struggle to keep up with the high cost of healthcare, even with insurance. This week, Congress debated ways to ...